NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

UCLA's ATL is NOT DCVax-L. DCVax-L is over 20 year old product and UCLA has had 20 years to continually improve the technology which is UCLA's property. UCLA is using their ATL in NSCLC and the NIH SPORE trial NOT DCVax-L. They have added new components that are NOT part of DCVax-L.

Dr. Robert Prins of UCLA, one of the lead clinicians in the SPORE GBM Combo trial has confirmed that. All of the ATL manufacturing are using UCLA vendors and NONE of the NWBO vendors. Not Advent or Cognent.

NWBO has made NO mention of the SPORE trials in their SEC filings, press releases, or other communications. Only naive shareholders have been claiming it as DCVax-L. If it was UCLA would be obligated to call it DCVax-L as that is the generic name of the treatment. But they are NOT.

Good luck if the Combo trial is an investment criteria. It is NOT NWBO's treatment, data and not going to be part of any regulatory applications because of that.